Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityNo recent work listed

Shiro Kohi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5058731156. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 6 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 4 papers

Papers 21

  1. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. First author DOI 10.1002/ijc.33883↗
  2. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2020.11.006↗
  3. Concurrent Overexpression of Two Hyaluronidases, KIAA1199 and TMEM2, Strongly Predicts Shorter Survival After Resection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002106↗
  4. Prognostic and functional role of hyaluronan-binding protein 1 in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2022.13343↗
  5. Hypoxia increases KIAA1199/CEMIP expression and enhances cell migration in pancreatic cancer. Co-author DOI 10.1038/s41598-021-97752-z↗
  6. Hypoxia Increases KIAA1199/CEMIP Expression and Enhances Cell Migration in Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-219524/v1↗
  7. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2019.10.036↗
  8. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Co-author DOI 10.1016/j.jmoldx.2020.02.010↗
  9. Overexpression of transmembrane protein 2 (TMEM2), a novel hyaluronidase, predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.08.026↗
  10. Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.27172↗
  11. 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. Co-author DOI 10.3892/ol.2018.8147↗
  12. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2016.12.007↗
  13. KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer. Co-author DOI 10.18632/oncotarget.15052↗
  14. A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells. Co-author DOI 10.1007/s10585-015-9771-9↗
  15. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.apsb.2016.01.002↗
  16. Increased Expression of HYAL1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000670↗
  17. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. First author DOI 10.1111/cas.12913↗
  18. Hyaluromycin, a Novel Hyaluronidase Inhibitor, Attenuates Pancreatic Cancer Cell Migration and Proliferation. Co-author DOI 10.1155/2016/9063087↗
  19. Hyaluronan stimulates pancreatic cancer cell motility. First author DOI 10.18632/oncotarget.6617↗
  20. Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.12990↗
  21. Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0080765↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Norihiro Sato · 17 shared papers, 2013–2022 · strength 1.68
  2. Keiji Hirata · 16 shared papers, 2015–2022 · strength 1.62
  3. Atsuhiro Koga · 13 shared papers, 2015–2022 · strength 1.25
  4. Yuzan Kudo · 6 shared papers, 2019–2022 · strength 0.83
  5. Yasuhiro Adachi · 5 shared papers, 2020–2022 · strength 0.71
  6. Michael Goggins · 6 shared papers, 2016–2022 · strength 0.66
  7. Xiaobo Cheng · 8 shared papers, 2013–2018 · strength 0.60
  8. Takuya Oba · 4 shared papers, 2021–2022 · strength 0.60
  9. Toshiya Abe · 4 shared papers, 2020–2022 · strength 0.45
  10. Toshiyuki Nakayama · 3 shared papers, 2020–2022 · strength 0.43
  11. Marcia Irene Canto · 3 shared papers, 2020–2022 · strength 0.32
  12. Alison P. Klein · 3 shared papers, 2020–2022 · strength 0.30
  13. Ralph H. Hruban · 3 shared papers, 2020–2022 · strength 0.30
  14. Ki Byung Song · 2 shared papers, 2020–2022 · strength 0.22
  15. Jin Peng He · 2 shared papers, 2020 · strength 0.17
  16. Richard Andrew Burkhart · 2 shared papers, 2020 · strength 0.17
  17. James R. Eshleman · 2 shared papers, 2020 · strength 0.17
  18. Eun Ji Shin · 1 shared paper, 2022 · strength 0.15
  19. Takeichi Yoshida · 1 shared paper, 2022 · strength 0.15
  20. Anne Marie Lennon · 1 shared paper, 2022 · strength 0.15
  21. Makoto Kawamoto · 1 shared paper, 2022 · strength 0.13
  22. Nicholas Jason Roberts · 1 shared paper, 2022 · strength 0.13
  23. Daniel A. Laheru · 1 shared paper, 2022 · strength 0.13
  24. Koji Tamura · 1 shared paper, 2020 · strength 0.09
  25. Christopher L. Wolfgang · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.